Sequent Scientific to acquire Arvee Synthesis

Sequent Scientific Ltd has entered into a definitive agreement to acquire the manufacturing assets and business of Arvee Synthesis Pvt Ltd, Mysore, Karnataka. Arvee would serve as a site for key intermediate for the company's human active pharmaceutical ingredient (API) business. The site has all necessary approvals and infrastructure with space for future expansion of Sequent's rapidly expanding business.
 
In another development, Sequent also acquired about 14 acres of land adjacent to its existing FDA approved facility in Mangalore. The facility at Mysore and land at Mangalore would be used for meeting the growing demand of Sequent's key products in the US FDA and WHO regulated markets.
 
Manish Gupta, CEO, Sequent, said, “Sequent's strategy of focusing on small, niche molecules is paying dividends. The human API business of Sequent is poised to grow at a CARG of 50% plus in the medium term, on the back of regulatory approvals of its key products in the regulated markets.”